Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07239895

Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells

Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.

Recruiting

Interested in participating?

Request Info

Key information

Age range

28 day–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University

Shanghai, 200000, China

Location status: Recruiting

Location contact

About this study

The study is co-sponsored by Regend Therapeutics and Shanghai Children's Hospital.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, aged between 28 days and 18 years;
  • Diagnosed with bronchiolitis obliterans according to the guidelines;
  • Meeting at least one of the following: FEV1 < 55% of predicted value; requiring continuous assisted mechanical ventilation or oxygen therapy;
  • None of acute infections within the past four weeks;
  • Tolerating bronchoscopy;
  • The child and/or parent(s) provide informed consent, and are able to understand and adhere to scheduled visits, treatments, laboratory tests, and other study procedures.

Exclusion criteria

  • Subjects with bronchiolitis obliterans syndrome (BOS) who are on a current cGVHD treatment regimen at screening.
  • At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody test. Hepatitis B virus carriers with stable current condition can be enrolled. Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test can be enrolled as well.
  • Subject who is assessed to have major lung diseases other than BO by investigators at screening or who has other severe systemic diseases within 6 months prior to screening and is considered to be unsuitable for this study by investigators.
  • Presence of severe coagulation dysfunction at screening and may compromise the safety of bronchoscopy in the investigator's judgment.
  • Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet aggregation therapy, and for whom, in the investigator's assessment, the medication cannot be discontinued within a week prior to cell collection and infusion.
  • Subjects with suicide risk or a history of psychiatric disorders at screening.
  • Participation in another interventional clinical study within 3 months prior to screening.
  • Poor compliance, making him or her difficult to complete the study.
  • Subjects who is considered to be unsuitable for this study in in the opinion of the investigator.

Treatment and study plan

Airway Basal Stem Cells

Biological

Airway Basal Stem Cells

Primary outcomes

  1. Change in clinical symptoms

    Time frame: 12 and 24 weeks after treatment

    Cough, wheezing, respiratory rate are included in clinical symptomes. Both status and frequency would be evaluated.

  2. Changes in oxygen therapy

    Time frame: 24 weeks after treatment

    Oxygen saturation (SpO₂), oxygen therapy settings, and daily duration of oxygen therapy would be evaluated.

Secondary outcomes

  1. Changes in general condition

    Time frame: 24 weeks after treatment

    Rate of weight gain, time of independent activity are evaluated as general condition.

  2. Change in lung diffusing capacity for carbon monoxide (DLCO) from baseline

    Time frame: 12 and 24 weeks after treatment

    DLCO is a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.

  3. Change in forced expiratory volume in one second (FEV1) from baseline

    Time frame: 12 and 24 weeks after treatment

    FEV1 is the volume of breath exhaled with effort in one second.

  4. Change in forced vital capacity (FVC) from baseline

    Time frame: 12 and 24 weeks after treatment

    FVC is the full amount of air that can be exhaled with effort in a complete breath

  5. Change in high resolution computed tomography (HRCT) from baseline

    Time frame: 24 weeks after treatment

    HRCT scan is a type of CT scan that shows detailed pictures of lungs

  6. Bronchiolitis Obliterans (BO) exacerbation

    Time frame: 24 weeks after treatment

    Frequency and severity of events will be evaluated

Study contacts

Contact information is provided by the study sponsor or research team.

Liling Qian, Professor and Chief Physician

CONTACT

[email protected]

086-021-62474880

Sponsors and collaborators

Lead sponsor

Regend Therapeutics

Industry

Collaborators

  • Shanghai Children's Hospital

Registry information

Official study title

Exploratory Study of Airway Basal Stem Cells on Treatment of Pediatric Bronchiolitis Obliterans

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Nov 20, 2025
Registry last updated
Jan 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.